Anti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs and the wound healing process

Journal of Cancer Science and Therapy

Volumn 4, Issue 10, 2012, Pages 324-329

  Casacó, Angel ^a   Fuente, Dasha ^b   Ledón, Nuris ^a   Fernández, Aymara ^a   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Biomodels Unit   (Cuba)

Author keywords

Cetuximab; Cimavax; Erlotinib; Gefitinib; Her 1 vaccine; Nimotuzumab; Panitimumab

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NIMOTUZUMAB; PANITUMUMAB; SIPULEUCEL T;

ALOPECIA; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; DRY SKIN; EMERGENCY SURGERY; ESOPHAGUS TUMOR; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HUMAN; HYPERTRICHOSIS; IMMUNIZATION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NONHUMAN; PANCREAS CANCER; PARONYCHIA; PROSTATE CANCER; REVIEW; SKIN; SKIN FISSURE; SURGICAL TECHNIQUE; TREATMENT INDICATION; VACCINATION; WOUND HEALING;

EID: 84869055306     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000162     Document Type: Review

References (44)

1. Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835-870.
2. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, et al. (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16: 16-26.
3. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, et al. (2001) Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 276: 18265-18271.
4. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: S3-S8.
5. Mellor JD, Cassumbhoy M, Jefford M (2011) Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol 7: 106-113.
6. Hompes D, Ruers T (2011) Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 37: 737-746.
7. Nakamura Y, Sotozono C, Kinoshita S (2001) The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 72: 511-517.
8. Foerster CG, Cursiefen C, Kruse FE (2008) Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 27: 612-614.
9. Kaftan H, Reuther L, Miehe B, Hosemann W, Herzog M (2008) Delay of tympanic membrane wound healing in rats with topical application of a tyrosine kinase inhibitor. Wound Repair Regen 16: 364-369.
10. Lee SM, Buchler T, Joseph T, Lai C (2008) Bilateral eardrum perforation after long-term treatment with erlotinib. J Clin Oncol 26: 2582-2584.
11. Márquez EB, De Ortueta D, Royo SB, Martínez-Carpio PA (2011) Epidermal growth factor receptor in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol 30: 7-14.
12. Dean NR, Sweeny L, Harari PM, Bonner JA, Jones V, et al. (2011) Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. J Wound Care 20: 166-170.
13. Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, et al. (2007) A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13: 986-993.
14. Parikh AA, Ellis LM (2008) Targeted therapies and surgical issues in gastrointestinal cancers. Target Oncol 3: 119-125.
15. Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, et al. (1995) alpha- Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 61: 342-347.
16. Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P, et al. (2004) Alpha-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci 5: 475-485.
17. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, et al. (2006) Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12: 617-625.
18. Govindan R, Behnken D, Read W, McLeod H (2003) Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib. Ann Oncol 14: 1330-1331.
19. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, et al. (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22: 1646-1654.
20. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, et al. (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98: 749-755.
21. González JE, Barquinero JF, Lee M, García O, Casaco A (2012) Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther 13: 71-76.
22. You B, Brade A, Magalhaes JM, Siu LL, Oza A, et al. (2011) A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs 29: 996-1003.
23. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, et al. (2010) Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16: 2474-2482.
24. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, et al. (2010) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9: 343-349.
25. Allan DG (2005) Nimotuzumab: evidence of clinical benefit without rash. Oncologist 10: 760-761.
26. Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, et al. (2009) Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 11: 27-33.
27. Perez R, Moreno E, Garrido G, Crombet T (2011) EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers 3: 2014-2031.
28. Garcia JA, Dreicer R (2011) Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park) 25: 242-249.
29. Rodriguez G, Gonzalez G, Crombet T, Lage A (2011) Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease. Expert Rev Respir Med 5: 337-342.
30. Gonzalez G, Crombet T, Lage A (2011) Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment. Curr Cancer Drug Targets 11: 103-110.
31. Casacó A, Díaz Y, Ledón N, Merino N, Vadés O, et al. (2004) Effect of an EGF-cancer vaccine on wound healing and inflammation models. J Surg Res 122: 130-134.
32. Ramírez BS, Pestana ES, Hidalgo GG, García TH, Rodríguez RP, et al. (2006) Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 119: 2190-2199.
33. Fuentes D, Chacón L, Casacó A, Ledón N, Fernández N, et al. (2012) Effects of an epidermal growth factor receptor-based cancer vaccine in the wound healing and inflammation processes in murine experimental models. Int Wound J.
34. Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, et al. (2003) Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg 90: 1261-1266.
35. Junemann-Ramirez M, Awan MY, Khan ZM, Rahamim JS (2005) Anastomotic leakage post-esophagogastrectomy for esophageal carcinoma: retrospective analysis of predictive factors, management and influence on longterm survival in a high volume centre. Eur J Cardiothorac Surg 27: 3-7.
36. McArdle CS, McMillan DC, Hole DJ (2005) Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg 92: 1150-1154.
37. Law WL, Choi HK, Lee YM, Ho JW, Seto CL (2007) Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy. J Gastrointest Surg 11: 8-15.
38. Lee WS, Yun SH, Roh YN, Yun HR, Lee WY, et al. (2008) Risk factors and clinical outcome for anastomotic leakage after total mesorectal excision for rectal cancer. World J Surg 32: 1124-1129.
39. Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, et al. (2011) Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol 104: 734-740.
40. Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, et al. (2011) Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol 22: 1886-1893.
41. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, et al. (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362: 527-533.
42. Brusevold IJ, Aasrum M, Bryne M, Christoffersen T (2012) Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. J Oral Pathol Med 41: 547-558.
43. Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, et al. (2012) Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck.
44. Pickhard AC, Margraf J, Knopf A, Stark T, Piontek G, et al. (2011) Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer 11: 388.